- Conditions
- Acute Coronary Syndrome, Angina, Unstable
- Interventions
- Ticagrelor, Eptifibatide, Clopidogrel
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 513
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Deoxycoformycin (DCF)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cladribine, Cytarabine, Gemtuzumab Ozogamicin, Recombinant Granulocyte Colony-Stimulating Factor, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myocardial Infarction, Thrombosis, Platelet Dysfunction
- Interventions
- Clopidogrel, Ticagrelor
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Coronary Artery Disease
- Interventions
- Adenosine, Contrast Media, Resting conditions
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 763 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Oklahoma City, Oklahoma
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Disease
- Interventions
- ticagrelor, prasugrel, Placebo
- Drug
- Lead sponsor
- Yochai Birnbaum
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- M3541, Palliative Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Coronary Artery Disease
- Interventions
- Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
- Procedure
- Lead sponsor
- Midwest Heart Foundation
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Roseville, California • Sacramento, California + 16 more
- Conditions
- Coronary Artery Disease
- Interventions
- Ticagrelor 180mg, Ticagrelor 90mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acute Coronary Syndrome, Coronary Artery Disease
- Interventions
- Ticagrelor, Clopidogrel, Optical Coherence Tomography
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 22
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
- Conditions
- Stable Coronary Artery Disease
- Interventions
- Ticagrelor, Clopidogrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Rebif® new formulation (RNF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
- Conditions
- Lung Transplant
- Interventions
- Regadenoson infusion
- Drug
- Lead sponsor
- Christine Lau, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Charlottesville, Virginia
- Conditions
- Leukemia, Myelocytic, Acute
- Interventions
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine, All-Trans Retinoic Acid (ATRA), Midostaurin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronary Arterial Disease (CAD), Peripheral Vascular Disease
- Interventions
- Aspirin, P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Healthy, Caffeine, Adenosine, Dopamine D2/3 Receptor Availability
- Interventions
- Caffeine (200 mg), Placebo
- Drug
- Lead sponsor
- Hsiao-Ying Wey
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Interventions
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Drug · Device
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • New York, New York
- Conditions
- Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
- Drug
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida